Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach
Abstract
Purpose: Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer. Patients and methods: We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options. Results: We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57-92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver). Conclusion: Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer. Trial registration: clinicaltrials.gov identifier NCT00805337.
AI evidence extraction
Main findings
Using a noninvasive biofeedback method, 1524 frequencies (0.1 Hz to 114 kHz) were identified in 163 cancer patients, with most frequencies (57–92%) reported as specific to a single tumor type. Compassionate treatment was offered to 28 patients; among 13 evaluable for response, 1 complete response (11 months), 1 partial response (13.5 months), and 4 cases of stable disease (4.0 to >34.1 months) were reported. Toxicity was limited to grade 1 fatigue in three patients, with no grade 2–4 toxicities reported.
Outcomes measured
- Identification of tumor-specific frequencies
- Adverse events/toxicity (NCI grading)
- Tumor response (complete response
- partial response
- stable disease)
- Feasibility/tolerability of administering tumor-specific frequencies
Limitations
- Noninvasive biofeedback method used to identify frequencies
- details not provided in abstract
- Compassionate-use treatment without stated control group
- Only 13/28 treated patients were evaluable for response
- Heterogeneous cancer types and metastatic sites
- Duration of exposure/treatment regimen not specified in abstract
- No SAR or field strength/exposure metrics reported in abstract
View raw extracted JSON
{
"study_type": "other",
"exposure": {
"band": "ELF",
"source": "therapeutic device/systemic delivery (amplitude-modulated electromagnetic fields)",
"frequency_mhz": null,
"sar_wkg": null,
"duration": null
},
"population": "Patients with various types of cancer; compassionate treatment in patients with advanced cancer and limited therapeutic options",
"sample_size": 163,
"outcomes": [
"Identification of tumor-specific frequencies",
"Adverse events/toxicity (NCI grading)",
"Tumor response (complete response, partial response, stable disease)",
"Feasibility/tolerability of administering tumor-specific frequencies"
],
"main_findings": "Using a noninvasive biofeedback method, 1524 frequencies (0.1 Hz to 114 kHz) were identified in 163 cancer patients, with most frequencies (57–92%) reported as specific to a single tumor type. Compassionate treatment was offered to 28 patients; among 13 evaluable for response, 1 complete response (11 months), 1 partial response (13.5 months), and 4 cases of stable disease (4.0 to >34.1 months) were reported. Toxicity was limited to grade 1 fatigue in three patients, with no grade 2–4 toxicities reported.",
"effect_direction": "mixed",
"limitations": [
"Noninvasive biofeedback method used to identify frequencies; details not provided in abstract",
"Compassionate-use treatment without stated control group",
"Only 13/28 treated patients were evaluable for response",
"Heterogeneous cancer types and metastatic sites",
"Duration of exposure/treatment regimen not specified in abstract",
"No SAR or field strength/exposure metrics reported in abstract"
],
"evidence_strength": "very_low",
"confidence": 0.74,
"peer_reviewed_likely": "yes",
"keywords": [
"amplitude-modulated electromagnetic fields",
"tumor-specific frequencies",
"biofeedback",
"compassionate treatment",
"advanced cancer",
"0.1 Hz",
"114 kHz",
"feasibility",
"toxicity",
"clinical response"
],
"suggested_hubs": []
}AI can be wrong. Always verify against the paper.
Comments
Log in to comment.
No comments yet.
NNEMF synthesis
Synthesis pending.